A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
All content for The Life Challenges Podcast is the property of Christian Life Resources and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
From Transition to Truth: A Journey with Katie Coblentz | Part 2
The Life Challenges Podcast
32 minutes
1 month ago
From Transition to Truth: A Journey with Katie Coblentz | Part 2
Katie Coblentz shares her powerful journey from identifying as transgender to finding her identity in Christ, revealing how Jesus' love filled the emptiness that transition couldn't satisfy. Katie shares how her transition initially felt effortless—"like pedaling downhill"—as society's affirmation created a smooth path forward. Yet seven years into living as "Caden," something wasn't right. The revelation that shook her came not from anti-transgender arguments but from a profound spiritual a...
The Life Challenges Podcast
A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
